Volume 7.04 | Feb 5

Prostate Cell News 7.04 February 5, 2016
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
Androgen Deprivation followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation
Scientists document that androgen treatment of androgen deprived prostate cancer cell lines resulted in a dose and time dependent induction of widespread double strand breaks. Generation of these breaks was dependent on androgen receptor and topoisomerase II beta but not on cell cycle progression. [Clin Cancer Res] Abstract
Learn More: Standardized Tools for Cancer Research
PUBLICATIONS (Ranked by impact factor of the journal)

Inhibition of O-GlcNAc Transferase Activity Reprograms Prostate Cancer Cell Metabolism
Scientists showed that inhibition of O-GlcNAc transferase activity inhibits the proliferation of prostate cancer cells, leads to sustained loss of c-MYC and suppresses the expression of CDK1, elevated expression of which predicts prostate cancer recurrence. [Oncotarget] Full Article

Exosomes Confer Pro-Survival Signals to Alter the Phenotype of Prostate Cells in Their Surrounding Environment
Researchers hypothesized that exosomes play a pivotal role in cell-cell communication in the local tumor microenvironment, conferring activation of numerous survival mechanisms during prostate cancer (PCa) progression and development of therapeutic resistance. Their in vitro results demonstrate that PCa derived exosomes significantly reduce apoptosis in LNCaP and RWPE-1 cells increase cancer cell proliferation and induce cell migration. [Oncotarget] Full Article

Evaluation of Polymer Shielding for Adenovirus Serotype 6 (Ad6) for Systemic Virotherapy against Human Prostate Cancers
Lower seroprevalence Ad6 was tested as a systemic therapy for prostate cancer. Ad5 and Ad6 were injected intravenously a single time in nude mice bearing human prostate tumors, and toxicity and efficacy were assessed. [Mol Ther] Full Article

EC-70124, a Novel Glycosylated Indolocarbazole Multi-Kinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB
Researchers showed that EC-70124 blocked concomitantly NF-κB and STAT3 in prostate cancer cells and particularly prostate cancer stem cells, which exhibited over-activation of these transcription factors. [Mol Cancer Ther] Abstract

Gene Expression Signatures Associated with Suppression of TRAMP Prostate Carcinogenesis by a Kavalactone-Rich Kava Fraction
Scientists evaluated the chemopreventive effect of a kavalactone-rich Kava fraction B, free of flavokavains, on carcinogenesis in a transgenic adenocarcinoma of mouse prostate (TRAMP) model and characterized the prostate gene expression signatures. [Mol Carcinog] Abstract

A Transcriptional Target of Androgen Receptor, miR-421 Regulates Proliferation and Metabolism of Prostate Cancer Cells
This study identified an androgen receptor (AR)-repressed microRNA, miR-421, in prostate cancer. Expression of miR-421 was significantly suppressed by androgen treatment, and correlated to AR expression in different prostate cancer cell lines. [Int J Biochem Cell Biol] Abstract

Phosphoproteome Analysis Demonstrates the Potential Role of THRAP3 Phosphorylation in Androgen-Independent Prostate Cancer Cell Growth
Investigators performed a comparative phosphoproteome analysis using a prostate cancer cell line, LNCaP, and an LNCaP-derived androgen-independent cell line, LNCaP-AI, to identify phosphoproteins involved in this mechanism. [Proteomics] Abstract

De Novo Steroid Biosynthesis in Human Prostate Cell Lines and Biopsies
The authors performed comparative gene expression analyses between various prostate cell lines and biopsies, including normal, hyperplastic, cancerous, and androgen-deprived prostate cells lines, as well as normal, benign prostate hyperplasia, prostate cancer, and castration-resistant prostate cancer human specimens. [Prostate] Abstract


Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer
Men with pathologically confirmed prostate cancer and radiologic progression of bone lesions in the 28 days prior to randomization were assigned to receive abituzumab or or placebo every three weeks in combination with luteinizing hormone-releasing hormone agonist/antagonist therapy. [Clin Cancer Res] Abstract

Severe Neutropenia during Cabazitaxel Treatment Is Associated with Survival Benefit in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post-Hoc Analysis of the TROPIC Phase III Trial
Data from the experimental arm of the TROPIC Phase III trial which randomly assigned men with mCRPC to cabazitaxel or mitoxantrone every three weeks, both combined with daily prednisone, were analysed. [Eur J Cancer] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now
Regulation of Prostate Cancer Progression by the Tumor Microenvironment
Researchers review the current data on the intricate relationship between inflammation, reactive stroma, tumor cells and disease progression in prostate cancer. [Cancer Lett] Abstract

The Importance of Non-Nuclear AR Signaling in Prostate Cancer Progression and Therapeutic Resistance
The authors review canonical androgen receptor (AR) signaling, but focus on AR non-genomic signaling, some of its downstream targets and how these effectors contribute to prostate cancer cell behavior. [Cell Signal] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Steba Biotech Completes its European Phase III Clinical Trial of TOOKAD® in Patients with Low-Risk Prostate Cancer and Submits Marketing Authorization Application to the European Medicine Agency
Steba Biotech announced completion of PCM301, its European Phase III clinical trial of TOOKAD® (padeliporfin di-potassium), a novel investigational treatment for localized prostate cancer and other solid tumors. [Steba Biotech] Press Release

VolitionRx Initiates Prostate Cancer Study in Collaboration with the Surrey Cancer Research Institute, University of Surrey, UK
VolitionRx Limited announced that it has initiated a study to assess the feasibility of using the company’s NuQ® blood tests to detect prostate cancer. The study is in collaboration with the Surrey Cancer Research Institute of the University of Surrey in the UK. [VolitionRx Limited] Press Release

With FDA Clearance, Focal Healthcare Will Make Targeted Prostate Biopsy Procedures Accessible to All Patients
Focal Healthcare Inc.™ announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for their targeted prostate biopsy device, Fusion Bx™. [Focal Healthcare Inc.] Press Release

From our sponsor:
Learn about mucociliary differentiation of primary bronchial epithelial cells.
Watch the video.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 3rd Immunotherapy of Cancer Conference (ITOC)
March 21-23, 2016
Munich, Germany

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Fellowship – Prostate Cancer and Cancer Metabolism (Cleveland Clinic)

Post-Doc Fellowship – Metastasis of Cancer (University of Arizona Cancer Center)

Post-Doc Fellowship – Molecular Imaging for Prostate Cancer (Case Western Reserve University)

Post-Doc Fellowship/Staff Scientist – Prostate Cancer Epidemiology (Memorial Sloan Kettering Cancer Center)

Postdoctoral Researcher – Prostate Cancer Biology (Roswell Park Cancer Institute)

Faculty Position – Urology Research (Mayo Clinic)

Post-Doc Fellowship – Cancer Stem Cell Biology (Weill Cornell Medical College)

Postdoctoral Position – Bioinformatics (Princess Margaret Cancer Centre)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us